Johnson & Johnson Stock-Based Compensation 2012-2026 | JNJ
Johnson & Johnson annual/quarterly stock-based compensation history and growth rate from 2012 to 2026. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- Johnson & Johnson stock-based compensation for the quarter ending March 31, 2026 was $1.354B, a 15.14% increase year-over-year.
- Johnson & Johnson stock-based compensation for the twelve months ending March 31, 2026 was $3.385B, a 10.66% increase year-over-year.
- Johnson & Johnson annual stock-based compensation for 2025 was $1.354B, a 15.14% increase from 2024.
- Johnson & Johnson annual stock-based compensation for 2024 was $1.176B, a 1.2% increase from 2023.
- Johnson & Johnson annual stock-based compensation for 2023 was $1.162B, a 2.11% increase from 2022.
|
Johnson & Johnson Annual Stock-Based Compensation (Millions of US $) |
|
|---|---|
| 2025 | $1,354 |
| 2024 | $1,176 |
| 2023 | $1,162 |
| 2022 | $1,138 |
| 2021 | $1,135 |
| 2020 | $1,005 |
| 2019 | $977 |
| 2018 | $978 |
| 2017 | $962 |
| 2016 | $878 |
| 2015 | $874 |
| 2014 | $792 |
| 2013 | $728 |
| 2012 | $662 |
| 2011 | $621 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |